-
Arteta tells Arsenal fans not to fret over his future
-
Venezuela frees more political prisoners amid post-Maduro talks
-
Mexico's Indigenous chief justice hits back at discrimination
-
Werro upstages Hodgkinson to win thrilling Euro 800m gold
-
Werro wins 800m race for the ages, Warholm and Tamberi hit four
-
Werro upstages Hodgkinson to win Euro 800m gold
-
Jimenez rescues dramatic Wolves draw in Championship opener
-
Hurricane poised to hit Hawaii as El Nino stirs Pacific
-
Taliban govt to mark five years ruling Afghanistan
-
Ex-Cambridge professor at centre of plagiarism scandal found dead
-
Stocks slip in cautious trading after weak US retail sales data
-
Wildfire threatens Canada wine region
-
Gramercy Networks Announces New Global Ultra-Low Latency Financial Network Connecting Major Trading Hubs
-
'Normal guy' turned killer over US insurance industry grievances
-
NFL bans Falcons defender Pearce eight games for domestic violence
-
Norway's hurdles king Warholm wins fourth European title
-
US says 19 million recalled eggs pose deadly risk
-
Liverpool deal with Bezos consortium raises stakes in US battle for Premier League power
-
Former Cincinnati contenders suffer contrasting first-round fates
-
Colombia hopes for miracles as search for quake victims goes on
-
Argentina's Romero confirms Tottenham exit as Atletico move looms
-
Popovici, Quadarella mine more gold at Europeans as Marchand flexes in butterfly
-
Homeless, jobless: Colombia quake survivors 'left with nothing'
-
'I shot Mr Thompson': Stunning confession in US health exec's slaying
-
Cubans find rest on rooftops as blackouts drive them from home
-
San Francisco to host 2028 MLB All-Star Game
-
World champ McIntosh crashes out of Pan Pacs 400m free
-
Trump dismisses concerns over conditions on US aircraft carrier
-
T'Wolves set Garnett celebration for Celtics clash
-
Zambia resumes vote count after pause over violence
-
Popovici nails freestyle double with third men's European 200m gold
-
Wind spurs forest fire in western Germany, with scores evacuated
-
Premier League club Liverpool sell minority stake to Jeff Bezos consortium
-
Pakistan captain Babar in injury scare ahead of England opener
-
Italian police recover stolen Renoir, Cezanne and Matisse works
-
Mangione admits shooting health care CEO
-
Stocks slip in cautious trading, oil turns higher
-
UN warns sanctions chill is stopping Cuba aid
-
Colombia quake survivor faces life without triplet sisters
-
Alleged US healthcare CEO killer says will plead guilty to stalking
-
Bones of medieval kings saved from Spanish wildfire
-
France's Macron in hot water over jet ski picture
-
US retail sales weakest in over a year, consumer sentiment plunges
-
Nursing federation demands proper pay, protection on Ebola front line
-
In wildfire town, PM says UK must 'face up to climate change'
-
France upholds assisted dying law, strikes down social media ban for children
-
In town hit by wildfire, PM says UK must 'face up to climate change'
-
Body found after wildfire hits Croatian coastal town
-
UK parliament probe into Farage resumes after polls win
-
Arteta expects Maresca to do an 'unbelievable job' at Man City
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
V.Dantas--PC